Anticoagulant after prosthetic implantation or plate fixation for resection/curettage of primary bone tumor around the knee joint: effect of rivaroxaban

doi:10.3969/j.issn.2095-4344.2014.22.003

Abstract

Abstract:

BACKGROUND: In patients with primary bone tumor around the knee joint, deep venous thrombosis easily occurred after prosthetic implantation, lesion resection/curettage, bone grafting and plate fixation. Thus, this should be paid enough attention in the clinic.

OBJECTIVE: To explore effectiveness and safety of rivaroxaban to prevent the deep vein thrombosis of adult lap in patients with primary bone tumors undergoing prosthetic replacement or plate fixation after resection/curettage tumors.

METHODS: Forty adult patients with primary bone tumor around the knee joint diagnosed in Department of Bone and Soft Tissue Oncology, Xijing Hospital, Fourth Military Medical University of Chinese PLA from March 2011 to March 2012 were randomly enrolled in this study. They did not have affected deep venous thrombosis before treatment. They were randomly assigned to two groups. Control group (n=20) received lesion resection/curettage, prosthetic replacement or plate fixation, and then received usual care and physical prophylaxis. Treatment group (n=20) received rivaroxaban 10 mg/d orally for 14 days, besides the treatment in the control group. At 1 month after treatment, deep venous thrombosis and the incidence of deep venous thrombosis were evaluated in follow-up. Whether pulmonary embolism and severe hemorrhage occurred was observed in both groups.

RESULTS AND CONCLUSION: None deep venous thrombosis developed in the treatment group, however, two patients with deep venous thrombosis were found in the control group. There was no pulmonary embolism or severe hemorrhage in both groups. There was significant difference in the incidence of deep venous thrombosis between both groups (P < 0.05). Results suggested that rivaroxaban effectively reduced the occurrence of deep venous thrombosis in the patients with primary bone tumor around the knee joint, and showed good prevention and safety.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

全文链接：

Key words: bone neoplasms, knee joint, venous thrombosis, anticoagulants

CLC Number:

R318

Wang Qian, Wang Zhen, Guo Zheng, Chen Guo-jing, Wang Cai-ru, Lin Yao, Wu Zhi-gang. Anticoagulant after prosthetic implantation or plate fixation for resection/curettage of primary bone tumor around the knee joint: effect of rivaroxaban[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(22): 3456-3462.

Figures/Tables 2

References

[1] Hirsh J, Dalen J, Guyatt G,et al.The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians.Chest. 2001;119(1 Suppl):1S-2S.
[2] Warwick D.Prevention of venous thromboembolism in total knee and hip replacement. Circulation. 2012;125(17):2151- 2155.
[3] Geerts WH, Bergqvist D, Pineo GF,et al.Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S.
[4] 纪泉,赵立连,张耀南,等.人工关节置换术与深静脉血栓形成[J]. 中华创伤骨科杂志, 2006, 8(6): 573-576.
[5] Korte W.Cancer and thrombosis: an increasingly important association.Support Care Cancer. 2008;16(3):223-228.
[6] Khorana AA.Venous thromboembolism prevention in cancer outpatients.J Natl Compr Canc Netw. 2013;11(11): 1431-1438.
[7] Lip GY, Chin BS, Blann AD.Cancer and the prothrombotic state.Lancet Oncol. 2002;3(1):27-34.
[8] Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients.J Clin Oncol. 2006;24(3):484-490.
[9] Bergqvist D, Caprini JA, Dotsenko O,et al.Venous thromboembolism and cancer.Curr Probl Surg. 2007;44(3): 157-216.
[10] Couban S, Goodyear M, Burnell M,et al.Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer.J Clin Oncol. 2005;23(18):4063-4069.
[11] 张鸿彬,王晓毓,姜佳明,等.恶性肿瘤中心静脉置管并发血栓22例分析[J].现代肿瘤医学,2009, 17(7):1339-1340.
[12] 王喆,张云亭,郭志.恶性肿瘤与静脉血栓形成关系的研究进展[J].中国肿瘤临床, 2008, 35(24): 1429-1431.
[13] 时德.下肢深静脉血栓形成的危险因素和预防措施[J].中国医刊, 2011, 46(10): 88-91.
[14] 姚佳春,王鹏.恶性肿瘤并发下肢深静脉血栓形成5例[J].中国中医药咨讯,2009,1(5):92.
[15] 林莉,徐建明,王岩,等.恶性肿瘤合并静脉血栓形成35例临床研究[J].临床肿瘤学杂志,2010,15(2):153-156.
[16] 王绍霞.恶性肿瘤并发静脉血栓的原因分析及防治干预[J].中医学报,2010,25(4): 622-623.
[17] 牛李敏,付蕾,王峰,等.深静脉血栓形成对恶性肿瘤患者预后的影响及危险因素[J].郑州大学学报:医学版, 2012,47(3):401-403.
[18] 李伟栩,叶招明,杨迪生,等.肿瘤型假体重建膝关节周围原发性肿瘤切除后骨缺损[J].中华外科杂志, 2007, 45(10): 665-668.
[19] Caprini JA.Thrombosis risk assessment as a guide to quality patient care.Dis Mon. 2005;51(2-3):70-78.
[20] Maynard G, Jenkins IH, Merli GJ.Venous thromboembolism prevention guidelines for medical inpatients: mind the (implementation) gap.J Hosp Med. 2013;8(10):582-588.
[21] Wickham N, Gallus AS, Walters BN,et al.Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline.Intern Med J. 2012;42(6): 698-708.
[22] Piazza G, Nguyen TN, Morrison R,et al.Patient education program for venous thromboembolism prevention in hospitalized patients.Am J Med. 2012;125(3):258-264.
[23] Semchuk WM, Sperlich C.Prevention and treatment of venous thromboembolism in patients with cancer.Can Pharm J (Ott). 2012;145(1):24-29.
[24] Lippi G, Favaloro EJ, Cervellin G.Prevention of venous thromboembolism: focus on mechanical prophylaxis.Semin Thromb Hemost. 2011;37(3):237-251.
[25] 中华医学会骨科学分会.中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志,2009,29(6):602-604.
[26] 侯晓茹,狄柯坪.恶性肿瘤患者下肢深静脉血栓形成的早期诊断与防治[J].白求恩军医学院学报, 2007, 5(1): 7-8.
[27] Nay Min Tun，Thein Hlaing Oo.Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. Thrombosis. 2013; 2013: 183616.
[28] 李小鹰,王辰.内科住院患者静脉血栓栓塞症预防的中国专家建议[J].中华结核和呼吸杂志, 2009, 32(1): 3-8.
[29] Hogg K, Carrier M. Prevention and treatment of venous thromboembolism in patients with cancer.Ther Adv Hematol. 2012 ;3(1):45-58.
[30] Gafsou B, Samama CM.Prevention of venous thromboembolism in surgical patients.Rev Prat. 2011;61(9): 1221-1228.
[31] 李恒,隋福革,汪群,等.应用利伐沙班预防关节置换术后深静脉血栓形成[J].中国现代医生, 2011, 49(16): 72-73.
[32] Duggan ST, Scott LJ, Plosker GL.Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Drugs. 2009;69(13): 1829-1851.
[33] Albertsen IE, Larsen TB, Rasmussen LH,et al.Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.Drugs. 2012;72(13):1755-1764.
[34] Maratea D, Fadda V, Trippoli S,et al.Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.J Thromb Haemost. 2011;9(9):1868-1870.
[35] Reis A.Prevention and treatment of venous thromboembolism: the place of new oral anticoagulants.Rev Port Cardiol. 2012; 31 Suppl 1:45-50.
[36] Borris LC.Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Arch Orthop Trauma Surg. 2010;130(5):583-589.
[37] Turpie AG, Lassen MR, Eriksson BI,et al.Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.Thromb Haemost. 2011;105(3):444-453.
[38] 唐辉,黄金亮,李川,等.利伐沙班对骨科大手术后深静脉血栓预防作用的研究进展[J].国际外科学杂志, 2011, 38(11): 778-781.
[39] Stevenson M, Scope A, Holmes M,et al.Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.Health Technol Assess. 2009;13 Suppl 3:43-48.
[40] Kwong LM.Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.Vasc Health Risk Manag. 2011;7:461-466.